Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
Completed · Phase 2 · Has a placebo group
Conditions studied: Sleep Apnea, Obstructive
In brief
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on genioglossus muscle activity (EMG GG) during sleep in healthy control participants.
Key facts
- Study ID
- NCT02428478
- Run by
- Brigham and Women's Hospital
- People needed
- 17
- Starts
- 2015-03-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2017-03-30
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy control subjects
You may not qualify if…
- Cardiovascular disease other than well controlled hypertension
- Depression
Where it is running
- Sleep Disorders Research Program Brigham and Women's Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.